Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study

被引：1
|
作者：
Gui, L. [1 ]
He, X. [1 ]
Yang, J. [1 ]
Liu, P. [1 ]
Yan, Q. [1 ]
Shi, Y-K. [1 ]
机构：
[1] Chinese Acad Med Sci, Med Oncol Dept, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.807
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
683P
引用
收藏
页码：S855 / S856
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
  • [2] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
    Gui, L.
    Chen, X.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
  • [3] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [4] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
  • [5] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
    Adkins, Douglas
    Ley, Jessica
    Palka, Kevin
    Jacobs, Miriam
    Liu, Jingxia
    Oppelt, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
  • [6] Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
    Yoshino, Takayuki
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Monden, Nobuya
    Homma, Akihiro
    Okami, Kenji
    Onozawa, Yusuke
    Fujii, Masato
    Taguchi, Takahide
    de Blas, Barbara
    Beier, Frank
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 524 - 531
  • [7] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
  • [8] Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Zheng, Dandan
    Hair, Gleicy M.
    Ai, Lei
    Wang, Liya
    Goto, Daisuke
    Lerman, Nati
    Bidadi, Behzad
    Hanna, Glenn J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [10] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345